University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Emily K. Bergsland, MD

Emily K. Bergsland, MD

Professor of Clinical Medicine, UCSF; Associate Director for Education, Helen Diller Family Comprehensive Cancer Center
Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

My research efforts are focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the GI Oncology site committee and an active member of the Phase I committee at UCSF. Nationally, I am co-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, a member of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS), and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am also study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research is focused on publishing the results of three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004).

Education

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982
 


Professional Experience

  • 1989-92
    Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92
    Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92
    Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92
    Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992
    Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • Transgenic mouse models of tumorigenesis
  • 1996-1992
    Clinical Instructor, Dept. of Medicine (Division of Hematology/Oncology), UCSF
  • 1998-2002
    Assistant Clinical Professor, Dept of Medicine (Division of Hematology/Oncology), UCSF
  • 2003-2002
    Associate Director, Hematology/Oncology Fellowship Program, UCSF
  • 2004-present
    Associate Professor, Dept. of Medicine, Division of Hematology/Oncology, UCSF
  • 2006-present
    Director of Education and Fellowship Program Director, Hematology/Oncology

Honors & Awards

  • 1982
    Phi Beta Kappa
  • 1985-82
    Vine Scholarship, University of Minnesota
  • 1982
    May Sine Peterson Award, University of Minnesota
  • 1982
    Alpha Omega Alpha
  • 1995-92
    Molecular Medicine Fellowship, University of California San Francisco

Selected Publications

  1. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul; 46(6):707-714.
    View on PubMed
  2. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 Jul; 46(6):715-731.
    View on PubMed
  3. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 Jul; 22(7):768-773.
    View on PubMed
  4. Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol. 2017 May; 34(5):88.
    View on PubMed
  5. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22.
    View on PubMed
  6. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 Mar 10.
    View on PubMed
  7. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017 Mar; 46(3):416-426.
    View on PubMed
  8. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874.
    View on PubMed
  9. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400.
    View on PubMed
  10. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23.
    View on PubMed
  11. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May; 23(5):411-8.
    View on PubMed
  12. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016 Aug; 23(8):2548-55.
    View on PubMed
  13. Mulvey CK, Bergsland EK. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):63-82.
    View on PubMed
  14. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
    View on PubMed
  15. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21.
    View on PubMed
  16. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40.
    View on PubMed
  17. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90.
    View on PubMed
  18. Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2015 Sep; 16(9):1046.
    View on PubMed
  19. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91.
    View on PubMed
  20. Bergsland EK. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? J Clin Oncol. 2015 May 10; 33(14):1523-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI